2021

Frankenfeld CL, Hakes JK, Leslie TF. 2021. All-cause mortality and residential racial and ethnic segregation and composition as experienced differently by individual-level race, ethnicity, and gender: Mortality Disparities in American Communities data. Ann Epidemiol 65:38-45, https://doi.org/10.1016/j.annepidem.2021.10.008.

View Abstract

2020

Levin-Sparenberg E, Bylsma LC, Lowe K, Sangare L, Fryzek JP, Alexander DD. 2020. A systematic literature review and meta-analysis describing the prevalence of KRAS, NRAS, and BRAF gene mutations in metastatic colorectal cancer. Gastroenterol Res 13(5):184–198. doi: 10.14740/gr1167.

View Abstract

Cohen SS, Roger VL, Weston SA, Jiang R, Movva N, Yusuf AA, Chamberlain AM. 2020. Evaluation of claims-based computable phenotypes to identify heart failure patients with preserved ejection fraction. Pharmacol Res Persp 8(6):e00676; doi: 10.1002/prp2.676.

View Abstract

Bylsma LC, Gillezeau C, Garawin TA, Kelsh MA, Fryzek JP, Sangaré L, et al. 2020. Prevalence of RAS and BRAF mutations in metastatic colorectal cancer patients by tumor sidedness: A systematic review and meta-analysis. Cancer Med 9(3):1044–1057.

View Abstract

Li S, Liu J, Gong T, Guo H, Gawade PL, Kelsh MA, et al. 2020. Duration of short-acting granulocyte colony-stimulating factor for primary prophylaxis and risk of neutropenia-related hospitalization in older patients with cancer. J Geriatr Oncol 11(8):1309–1315.

View Abstract

Li S, Peng Y, Liu J, Li S, Raskin L, Kelsh MA, et al. Variations in hospitalization and emergency department/observation stays using the oncology care model methodology in Medicare data. 2020. Curr Med Res Opin 36(9):1519–1527.

View Abstract

Gawade PL, Li S, Henry D, Smith N, Belani R, Kelsh MA, et al. Patterns of granulocyte colony-stimulating factor prophylaxis in patients with cancer receiving myelosuppressive chemotherapy. 2020. Support Care Cancer 28(9):4413–4424.

View Abstract

Hawkins A, Murphy A, McNamara M, Gawade PL, Belani R, Kelsh MA. A survey of oncologists’ perceptions and opinions regarding the use of granulocyte colony-stimulating factors. 2020. J Cancer Edu 35(1):178–186.

View Abstract

Locatelli F, Whitlock JA, Peters C, Chen-Santel C, Chia V, Dennis RM, … Kelsh MA, et al. 2020. Blinatumomab versus historical standard therapy in pediatric patients with relapsed/refractory Ph-negative B-cell precursor acute lymphoblastic leukemia. Leukemia 34(9):2473–2478.

View Abstract

Ravandi F, Pierce S, Garcia-Manero G, Kadia T, Jabbour E, Borthakur G, … Kelsh M, et al. 2020. Salvage therapy outcomes in a historical cohort of patients with relapsed or refractory acute myeloid leukemia. Clin Lymphoma Myeloma Leuk 20(11):e871–e882.

View Abstract